Table 3:
All N = 1910 |
Tumor size ≤39mm N = 1027 |
Tumor size 40– 69mm N = 528 |
Tumor size 70– 99mm N = 212 |
Tumor size ≥100mm N = 143 |
Z-statistic & P-value for monotonic trend† |
|
---|---|---|---|---|---|---|
Open conversion, n (%) | 63 (3.3%) | 22 (2.1)% | 18 (3.4%) | 13 (6.1%) | 10 (7.0%) |
Z=3.90;
P<0.001 |
Median operating time (IQR), min | 160 (112–215) | 155 (105–215) | 157 (112–210) | 180 (120–220) | 180 (126–235) |
Z=3.84,
P<0.001 |
Median blood loss (IQR), ml | 100 (50–200) | 50 (30–153) | 100 (50–200) | 100 (50–250) | 200 (50–300) |
Z=6.50;
P<0.001 |
Intraoperative blood transfusion, n (%) | 60 (3.1%) | 19 (1.9%) | 16 (3.0%) | 11 (5.2%) | 14 (9.8%) |
Z=5.15;
P<0.001 |
Pringle maneuver applied, n (%) | 365/1868 (19.5%) | 157/1011 (15.5%) | 99/514 (19.3%) | 60 (28.8%) | 48/135 (35.6%) |
Z=6.48;
P<0.001 |
Median postoperative stay (IQR), days | 5 (3–6) | 5 (4–6) | 5 (3–6) | 5 (3–6) | 5 (3–6) | Z=0.84; P=0.399 |
Overall morbidity, n (%) | 255/1909 (13.4%) | 125/1026 (12.2%) | 80/528 (15.2%) | 32/212 (15.1%) | 18/143 (12.6%) | Z=0.97; P=0.330 |
Major morbidity (Clavien-Dindo grade>2) | 52/1909 (2.7%) | 24/1026 (2.3%) | 12/528 (2.3%) | 8/212 (3.8%) | 8/143 (5.6%) |
Z=2.17;
P=0.030 |
30-day readmission, n (%) | 44/1901 (2.3%) | 17/1021 (1.7%) | 15/527 (2.8%) | 7/211 (3.3%) | 5/142 (3.5%) |
Z=1.99;
P=0.047 |
30-day mortality, n (%) | 7 (0.4%) | 2 (0.2%) | 3 (0.6%) | 1 (0.5%) | 1 (0.7%) | Z=1.19; P=0.233 |
90-day mortality, n (%) | 12 (0.6%) | 4 (0.4%) | 4 (0.8%) | 3 (1.4%) | 1 (0.7%) | Z=1.34; P=0.180 |
Close margins, n (%) | 110/1902 (5.8%) | 54/1020 (5.3%) | 44/528 (8.3%) | 6/212 (2.8%) | 6/142 (4.2%) | Z=−0.57; P=0.571 |
Two-sided Cochran-Armitage or Jonckheere-Terpstra tests were used to evaluate the presence of a monotonic increasing or decreasing trend over the four tumor size categories, which was treated as an ordinal variable (i.e., Group 1: <40mm, Group 2: 40–69mm, Group 3: 70–99mm, Group 4: ≥100mm).
IQR interquartile range